IMPLANTICA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.4 SEK | +0.37% |
|
-5.35% | +14.64% |
| Sales 2023 | 1.41M 1.51M 16.47M | Sales 2024 * | 3.6M 3.86M 42.1M | Capitalization | 660M 708M 7.72B |
|---|---|---|---|---|---|
| Net income 2023 | -23M -24.65M -269M | Net income 2024 * | -36M -38.58M -421M | EV / Sales 2023 | 369 x |
| Net cash position 2023 | 87.92M 94.23M 1.03B | Net cash position 2024 * | 50.95M 54.6M 596M | EV / Sales 2024 * | 169 x |
| P/E ratio 2023 |
-6.31
x | P/E ratio 2024 * |
-3.7
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 4.86% |
More Fundamentals
* Assessed data
More news
Latest transcript on Implantica AG
| 1 day | +0.37% | ||
| 1 week | -5.35% | ||
| Current month | -12.46% | ||
| 1 month | -12.46% | ||
| 3 months | -3.18% | ||
| 6 months | +63.88% | ||
| Current year | +14.64% |
1 week
26.90
29.40
1 month
26.9031.45
Current year
23.8033.00
1 year
15.4033.00
3 years
15.40136.80
5 years
15.40178.90
10 years
15.40178.90
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Forsell
CEO | Chief Executive Officer | 70 | 14-12-31 |
Andreas Öhrnberg
DFI | Director of Finance/CFO | 46 | 19-12-31 |
| Director/Board Member | 67 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tomas Puusepp
BRD | Director/Board Member | 69 | 19-12-31 |
Liselott Kilaas
CHM | Chairman | 65 | 19-12-31 |
Johan Bojs
BRD | Director/Board Member | 60 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 27.4 | +0.37% | 14,866 |
| 24-04-29 | 27.3 | -0.73% | 25,144 |
| 24-04-26 | 27.5 | +0.18% | 59,257 |
| 24-04-25 | 27.45 | -1.96% | 30,369 |
| 24-04-24 | 28 | -2.78% | 39,187 |
Delayed Quote Nasdaq Stockholm, April 30, 2024 at 06:59 am EDT
More quotes
Implantica AG is Lichtenstein-based medical technology Company, whose mission is to provide effective treatment for serious health conditions and to improve patients' life through the use of advanced technologies in the human body, ultimately aiming to reduce costs and increase efficiency in the healthcare System. The therapies developed by Implantica are based on implants that are inserted into the patient's body and remain in the body permanently or semi-permanently to replace bodily functions and/or treat diseases. The Company focuses on the discovery, development and prospective commercialization of medical products and implants that are intended for use in different treatment fields like in the area of gastrointestinal surgery and urology. The Company's lead product is RefluxStop, a passive, implant to prevent gastroesophageal reflux disease (GERD).
Calendar
2024-05-14
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.333
EUR
Average target price
3.834
EUR
Spread / Average Target
+64.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.64% | 706M | |
| +73.09% | 12.38B | |
| -18.39% | 7.61B | |
| +14.33% | 7.11B | |
| +4.77% | 5.83B | |
| +11.77% | 5.35B | |
| +29.65% | 4.63B | |
| -17.05% | 4.02B | |
| -35.92% | 2.16B | |
| +1.24% | 2.01B |
- Stock Market
- Equities
- IMP A SDB Stock
